Labcorp Holdings Inc Stock Price, News & Analysis

Labcorp (NYSE: LH) will release its financial results for Q2 2021 on July 29, 2021, before market open. A conference call will occur at 9 a.m. ET to discuss the results. Interested parties can access this call via dial-in or through a real-time webcast on the Labcorp Investor Relations website. An audio replay will be available from 1 p.m. ET on the same day until August 12, 2021. The company reported a revenue of $14.0 billion in FY2020, highlighting its position as a leader in global life sciences.

Labcorp (NYSE: LH) announces the launch of therascreen KRAS PCR Mutation Analysis, a companion diagnostic test to identify non-small cell lung cancer (NSCLC) patients eligible for LUMAKRAS™ (sotorasib) therapy. Approved by the FDA in May 2021, this test is crucial for directing treatment decisions for the 10-12% of lung cancer patients carrying the G12C KRAS mutation. Labcorp aims to enhance patient access to this innovative testing through collaboration with QIAGEN, contributing to personalized cancer care.

Molecular Loop Biosciences has announced that Labcorp (NYSE: LH) will utilize its SARS-CoV-2 Research Sequencing Panel to sequence thousands of coronavirus genomes weekly from patient samples. This initiative supports the CDC's efforts to monitor and track SARS-CoV-2 variants across the U.S. The sequencing panel streamlines the process of converting RNA samples into sequencer-ready libraries, enhancing scalability and data quality with redundant probe tiling technology. Molecular Loop aims to simplify genomic technology use in labs and enhance accessibility to genetic testing.

Labcorp (NYSE: LH) and OmniSeq are launching OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test designed to enhance precision oncology. This tissue-based test utilizes next-generation sequencing (NGS) technology to provide clinicians with evidence-based treatment recommendations tailored to individual patients, including potential clinical trial options. Available to U.S. clinicians via Labcorp and globally through biopharmaceutical companies, OmniSeq INSIGHT aims to improve patient outcomes by integrating cutting-edge diagnostic tools into care pathways.

Labcorp (NYSE: LH) has expanded the availability of its Pixel by Labcorp COVID-19 PCR Test Home Collection Kit to 6,000 Walgreens locations across the U.S. This initiative enhances testing access, particularly in underserved areas. Customers can purchase the kit at pharmacies or order via DoorDash and Instacart, allowing for convenient home testing. The kit is authorized for emergency use by the FDA. Labcorp aims to support community health amid the ongoing pandemic, with test results provided online and follow-up consultations available for positive cases.

Labcorp (NYSE: LH) announced the launch of its combined oncology platform at the virtual ASCO Annual Meeting from June 4-8, 2021. This platform integrates diagnostic testing and drug development services to enhance treatment options for cancer patients. Key offerings include OmniSeq® INSIGHT, a pan-cancer sequencing test, and IntelliGEN® Myeloid testing for myeloid malignancies. Labcorp aims to improve patient outcomes through precision medicine and better access to clinical trials, with insights being shared during a presentation by Dr. Robert Phillips.

Labcorp's new study reveals that nearly 87% of COVID-19 patients maintained antibodies for at least 10 months. Analyzing specimens from 39,086 individuals, the study highlights the body's sustained immune response, particularly for the SARS-CoV-2 spike protein. Notably, the positivity rate for spike antibodies remained stable, while nucleocapsid antibodies declined but stayed above 60% after 10 months. The research underscores Labcorp's role in understanding COVID-19 and may influence future vaccination strategies.

Labcorp (NYSE: LH) announced an expansion of its drug development services in the Asia-Pacific region by adding bioanalytical services in Singapore. This new laboratory will enhance the company's capabilities in bioanalytical studies, supporting both small and large molecular entities. Key offerings include Good Laboratory Practice-compliant bioanalysis and faster data turnaround for early-phase trials. Construction is already underway, with an expected opening in late 2021. Labcorp aims to strengthen its position in a critical market, providing vital services to clients in the region.

Labcorp (NYSE: LH) will have its executive management team participate in a virtual fireside chat at the UBS Global Healthcare Virtual Conference on May 24 at 3:00 p.m. ET. A live webcast of the event will be accessible via the Investor Relations section on www.Labcorp.com and will also be archived for future viewing.

Labcorp is a leading life sciences company, reporting $14.0 billion in revenue in FY2020 and employing over 70,000 people globally, providing essential information to aid health decision-making.